Charles River Laboratories International Inc
NYSE:CRL
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
178.58
273.43
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Charles River Laboratories International Inc
Charles River Laboratories International Inc
Accounts Payable
Charles River Laboratories International Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Charles River Laboratories International Inc
NYSE:CRL
|
Accounts Payable
$136m
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
17%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Accounts Payable
$2.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
|
|
Danaher Corp
NYSE:DHR
|
Accounts Payable
$1.6B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-1%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Accounts Payable
$202.9m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
5%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Accounts Payable
$497m
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
2%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Accounts Payable
$3.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
Charles River Laboratories International Inc
Glance View
Charles River Laboratories International Inc. is a leading provider of essential research services and products that support the global clinical development of new drugs. Founded in 1947, the company has evolved from a small laboratory in Massachusetts to a formidable player within the biotech and pharmaceutical sectors. Its comprehensive suite of offerings includes preclinical and clinical laboratory services, along with a range of research models that help organizations like pharmaceutical companies and academic institutions navigate the complexities of drug development. By partnering with clients from early-stage discovery through to advanced trials, Charles River plays a pivotal role in bringing innovative therapies to market while maintaining a strong commitment to animal welfare and ethical research practices. As an investment opportunity, Charles River Laboratories stands out due to its solid financial performance, buoyed by a strategic focus on expanding its capabilities and services. The company has shown robust revenue growth over the years, driven by increasing demand for outsourced laboratory services, especially as the biotech landscape becomes more competitive. With a dedicated management team and a continual investment in technology and infrastructure, Charles River is well-positioned to capitalize on the rising need for more efficient drug development processes. Investors can take confidence from the company's strong market presence, consistent execution, and strategic acquisitions that enhance its service offerings, making it a compelling choice for those looking to invest in the healthcare space.
See Also
What is Charles River Laboratories International Inc's Accounts Payable?
Accounts Payable
136m
USD
Based on the financial report for Sep 28, 2024, Charles River Laboratories International Inc's Accounts Payable amounts to 136m USD.
What is Charles River Laboratories International Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
17%
Over the last year, the Accounts Payable growth was 0%. The average annual Accounts Payable growth rates for Charles River Laboratories International Inc have been 2% over the past three years , 5% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet
